Effect of Different Probiotic Strains in Hypercholesterolemic Patients

Status Completed

Clinical Trial Summary

Regular probiotic use for 8 weeks was evaluated in individual with mild to moderate hyperlipidemia. Current study have been determined the use of different probiotics strains on lipid parameters such as; total cholesterol, HDL cholesterol, LDL cholesterol, triglyceride levels as well as glycemic parameters such as; glucose, insulin, HOMA-IR levels. Also, hs-CRP levels were investigated as inflammatory parameter.

Clinical Trial Description

In the light of recent studies, it has been shown that probiotics may have positive effects on hyperlipidemia. The aim of this study was to investigate the effect of probiotics mainly on blood lipids as well as homocysteine levels, glycemic control parameters and hs-CRP levels A randomized, double-blind placebo-controlled study was completed with a total of 51 individuals who have diagnosed with hyperlipidemia. Participants were randomly assigned into 3 groups according to the probiotic type they would consume, groups were as follows; Lactobacillus (probiotic group I) (n=18), Lactobacillus and Bifidobacterium (probiotic group II) (n=17) and placebo group (n= 16). They were all requested to have placebo or probiotic capsules every day for 8 weeks. Total cholesterol, HDL cholesterol, LDL cholesterol, triglyceride levels were investigated as lipid metabolism parameters while fasting blood glucose, insulin, HOMA-IR levels were investigated as glycemic parameters. Also, hs-CRP levels were investigated as inflammatory parameter. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04701775
Study type	Interventional
Source	Eastern Mediterranean University
Contact
Status	Completed
Phase	N/A
Start date	September 28, 2018
Completion date	March 7, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03793985` - Compare the Pharmacokinetics and Safety of CKD-391 With Co-administration of D086 and D337	Phase 1
Recruiting	`NCT03947866` - Ezetimibe-Rosuvastatin Evaluation Study
Withdrawn	`NCT04922424` - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men	Phase 1
Completed	`NCT04516291` - A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)	Phase 2
Completed	`NCT03632668` - Evaluating the Pharmacokinetic Interaction Between AD-2071 and AD-2072	Phase 1
Completed	`NCT03534661` - L-NMMA on GLP-2 Mediated Intestinal Lipoprotein Release	Phase 2/Phase 3
Completed	`NCT03422666` - Plasma Lipoprotein Response to Glucagon-like Peptide-2	Phase 2/Phase 3
Completed	`NCT00536796` - Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets	N/A
Completed	`NCT03643705` - A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention	N/A
Recruiting	`NCT04560296` - Community-based E-Health Program for Older Adults Living With Chronic Diseases	N/A
Terminated	`NCT04073134` - The CHORAL Flow Study	Phase 4
Recruiting	`NCT05103254` - Bempedoic Acid Pregnancy Surveillance Program
Not yet recruiting	`NCT05015348` - Effects of Omega-3 PUFA on Lipids, Inflammatory Factors and Body Composition in Patients With Hyperlipidemia	N/A
Active, not recruiting	`NCT05082350` - Nutritional Intervention With Black Garlic	N/A
Not yet recruiting	`NCT04398771` - To Evaluate Safety and Effectiveness of RovatitanTab.
Not yet recruiting	`NCT04064281` - The Healthy Cantonese Diet on Cardiometabolic Syndrome	N/A
Recruiting	`NCT06257641` - Impact of the Mediterranean Diet on Patients With Psoriasis	N/A
Completed	`NCT03690778` - The PK Characteristics of the Co-administration of Metformin SR and Rosuvastatin and JLP-1310 in Healthy Male Volunteers.	Phase 1
Completed	`NCT04354987` - Compare the Pharmacokinetics and Safety of CKD-391	Phase 1
Completed	`NCT03337308` - A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy	Phase 3